Haj Ahmed Wiem, Peiro Cécile, Fontaine Jessica, Ryan Barry J, Kinsella Gemma K, O'Sullivan Jeff, Grolleau Jean-Louis, Henehan Gary T M, Carpéné Christian
Institute of Metabolic and Cardiovascular Diseases, INSERM, UMR1048, Team 1, 31432 Toulouse, France.
I2MC, University of Toulouse, UMR1048, Paul Sabatier University, 31432 Toulouse, France.
Medicines (Basel). 2020 Apr 2;7(4):18. doi: 10.3390/medicines7040018.
Methylxanthines including caffeine and theobromine are widely consumed compounds and were recently shown to interact with bovine copper-containing amine oxidase. To the best of our knowledge, no direct demonstration of any interplay between these phytochemicals and human primary amine oxidase (PrAO) has been reported to date. We took advantage of the coexistence of PrAO and monoamine oxidase (MAO) activities in human subcutaneous adipose tissue (hScAT) to test the interaction between several methylxanthines and these enzymes, which are involved in many key pathophysiological processes. Benzylamine, methylamine, and tyramine were used as substrates for PrAO and MAO in homogenates of subcutaneous adipose depots obtained from overweight women undergoing plastic surgery. Methylxanthines were tested as substrates or inhibitors by fluorimetric determination of hydrogen peroxide, an end-product of amine oxidation. Semicarbazide-sensitive PrAO activity was inhibited by theobromine, caffeine, and isobutylmethylxanthine (IBMX) while theophylline, paraxanthine, and 7-methylxanthine had little effect. Theobromine inhibited PrAO activity by 54% at 2.5 mM. Overall, the relationship between methylxanthine structure and the degree of inhibition was similar to that seen with bovine PrAO, although higher concentrations (mM) were required for inhibition. Theobromine also inhibited oxidation of tyramine by MAO, at the limits of its solubility in a DMSO vehicle. At doses higher than 12 % v/v, DMSO impaired MAO activity. MAO was also inhibited by millimolar doses of IBMX, caffeine and by other methylxanthines to a lesser extent. This preclinical study extrapolates previous findings with bovine PrAO to human tissues. Given that PrAO is a potential target for anti-inflammatory drugs, it indicates that alongside phosphodiesterase inhibition and adenosine receptor antagonism, PrAO and MAO inhibition could contribute to the health benefits of methylxanthines, especially their anti-inflammatory effects.
包括咖啡因和可可碱在内的甲基黄嘌呤是广泛食用的化合物,最近有研究表明它们能与牛含铜胺氧化酶相互作用。据我们所知,迄今为止尚未有关于这些植物化学物质与人类初级胺氧化酶(PrAO)之间存在任何相互作用的直接证据报道。我们利用人类皮下脂肪组织(hScAT)中PrAO和单胺氧化酶(MAO)活性的共存,来测试几种甲基黄嘌呤与这些参与许多关键病理生理过程的酶之间的相互作用。在接受整形手术的超重女性的皮下脂肪库匀浆中,使用苄胺、甲胺和酪胺作为PrAO和MAO的底物。通过荧光法测定胺氧化的终产物过氧化氢,将甲基黄嘌呤作为底物或抑制剂进行测试。氨基脲敏感的PrAO活性受到可可碱、咖啡因和异丁基甲基黄嘌呤(IBMX)的抑制,而茶碱、对黄嘌呤和7-甲基黄嘌呤的影响较小。可可碱在2.5 mM时抑制PrAO活性达54%。总体而言,甲基黄嘌呤结构与抑制程度之间的关系与牛PrAO相似,尽管抑制所需的浓度更高(mM)。可可碱在其在二甲基亚砜载体中的溶解度极限下,也抑制了MAO对酪胺的氧化。当剂量高于12% v/v时,二甲基亚砜会损害MAO活性。MAO也受到毫摩尔剂量的IBMX、咖啡因以及其他甲基黄嘌呤较小程度的抑制。这项临床前研究将先前对牛PrAO的研究结果外推至人体组织。鉴于PrAO是抗炎药物的潜在靶点,这表明除了磷酸二酯酶抑制和腺苷受体拮抗作用外,PrAO和MAO抑制可能有助于甲基黄嘌呤对健康的益处,尤其是它们的抗炎作用。